Pfizer (NYSE:PFE) Shares Unloaded Rep. Josh Gottheimer

Key Points

• Representative Josh Gottheimer sold shares of Pfizer Inc. (NYSE:PFE) valued between $1,001 and $15,000 on June 3rd.
• Pfizer's stock recently traded at $24.73, with a 12-month high of $31.54 and a low of $20.92.
• The company announced a quarterly dividend of $0.43 per share, representing a yield of 6.95%.
• Analysts have a consensus rating of "Hold" for Pfizer, with a target price averaging $28.55.

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on July 16th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on June 3rd. The trade occurred in the Representative's "MORGAN STANLEY - ACTIVE ASSET ACCOUNT # 3" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/25/2025.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/20/2025.
• Purchased $1,001 - $15,000 in shares of Cloudflare NYSE: NET on 6/20/2025.
• Purchased $1,001 - $15,000 in shares of Carvana NYSE: CVNA on 6/20/2025.
• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 6/20/2025.

Pfizer Stock Performance

NYSE:PFE traded down $0.57 during mid-day trading on Friday, hitting $24.79. 35,628,980 shares of the company's stock traded hands, compared to its average volume of 38,205,096. The firm has a 50 day moving average of $24.30 and a two-hundred day moving average of $24.68. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market capitalization of $140.91 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the company earned $0.82 EPS. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.94%. Pfizer's dividend payout ratio is presently 124.64%.

Analysts Set New Price Targets

Several brokerages recently weighed in on PFE. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. The Goldman Sachs Group raised their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. BMO Capital Markets reduced their price objective on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, Bank of America raised their price objective on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $28.55.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Pfizer in the 4th quarter valued at $2,328,986,000. Pacer Advisors Inc. increased its stake in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after buying an additional 17,957,928 shares during the period. Amundi increased its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the period. Nuveen LLC acquired a new stake in shares of Pfizer in the 1st quarter valued at $389,861,000. Finally, Starboard Value LP acquired a new stake in shares of Pfizer in the 4th quarter valued at $407,730,000. 68.36% of the stock is owned by institutional investors and hedge funds.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.